ACNV (ACNV) Stock Price & Analysis
ACNV (ACNV) rose 0.00% to USD 0 as of June 11, 2026 at 03:32 UTC, according to Nexqual real-time market data.
ACNV last closed at USD 0; the session ranged USD 0–0 on volume of 99,991 shares. Market capitalization is $8,140, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 11, 2026 at 03:32 UTC.
Key Statistics (as of June 11, 2026 at 03:32 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 99,991 shares |
| Market Cap | $8,140 |
| Exchange | PNK |
Technical Analysis (ACNV)
Nexqual's technical model rates ACNV "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 11, 2026 at 03:32 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (ACNV)
Wall Street analysts rate ACNV "None", per Nexqual as of June 11, 2026 at 03:32 UTC.
| Consensus Rating | None |
|---|
Earnings (ACNV)
Source: Nexqual, June 11, 2026 at 03:32 UTC.
Financials & Fundamentals (ACNV)
| Total Revenue | $1,250 |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -41795.60% |
| Profit Margin | +0.00% |
| Total Debt | $1.52M |
Source: Nexqual, June 11, 2026 at 03:32 UTC.
Financial Health Score (ACNV)
Nexqual rates ACNV's overall financial health "Weak" across five dimensions, as of June 11, 2026 at 03:32 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — No data |
| Cash Flow | Weak — Operating cash flow -$60K |
| Efficiency | Mixed — No data |
Ownership (ACNV)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 81.41M |
| Float | 57.18M |
Source: Nexqual, June 11, 2026 at 03:32 UTC.
Leadership (ACNV)
ACNV is led by Geoffrey J. Thompson (age 57), Interim CEO & CFO, per Nexqual as of June 11, 2026 at 03:32 UTC.
| Interim CEO & CFO | Geoffrey J. Thompson (age 57) |
|---|
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ABMT | ADVANCED BIOMEDICAL TECHNOLOGIE | USD 0 | ▲ 0% |
| ADLI | AMERICAN MEDICAL TECHNOLOGIES | USD 0 | ▲ 0% |
| ADYX | ADYNXX INC | USD 0 | ▲ 0% |
| ADVT | ADVANTIS CORPORATION | USD 0 | ▲ 0% |
| ACBM | ACRO BIOMEDICAL CO LTD | USD 0.03 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 11, 2026 at 03:32 UTC. This page is informational and not investment advice.